Small cell lung cancer (SCLC) is highly aggressive with poor prognosis. Despite a relative
prevalence of circulating tumour DNA (ctDNA) in SCLC, liquid biopsies are not currently …

Treatments for cancer patients are becoming increasingly complex, and there is a growing
desire from clinicians and patients for biomarkers that can account for this complexity to …

Abstract Oxford Nanopore Technologies sequencing, also referred to as Nanopore
sequencing, stands at the forefront of a revolution in clinical genetics, offering the potential …

Liquid biopsies, in particular, analysis of cell-free DNA, are expected to revolutionize the
current landscape of cancer diagnostics and treatment. However, the existing methods for …

Background cfDNA fragmentomics-based liquid biopsy is a potential option for noninvasive
bladder cancer (BLCA) detection that remains an unmet clinical need. Methods We …

High cancer mortality rates and the rising cancer burden worldwide drive the development of
innovative methods in order to advance cancer diagnostics. Urine contains a viable source …

Background Aberrant embryo implantation and suboptimal placentation can lead to (severe)
complications such as preeclampsia and fetal growth restriction later in pregnancy. Current …

Identifying mutations in cancer-associated genes to guide patient treatments is essential for
precision medicine. Circulating tumor DNA (ctDNA) offers valuable insights for early cancer …

Simple Summary Cancer is a complex disease caused by a slew of genetic mutations
discovered through advances in sequencing technologies such as next-generation …

Biological information is encoded in a sequence of biochemical molecules such as nucleic
acids and amino acids, and nanopore sequencing is a long-read sequencing technology …